We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies
Sagar Lonial, MD, FACP
Caitlin Costello, MD
Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
Clinical Challenges With Triple-Class or Penta-Refractory MM
Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC
Charu Aggarwal, MD, MPH
Next-Generation TKI Therapy for ROS1-Rearranged NSCLC
Alexander Drilon, MD
Intracranial Activity of ROS1 TKIs
Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors
Considerations for Dosing Bispecific Antibodies
Step-Up Dosing of Bispecific Antibodies: The Need for Hospitalization
Preventing CRS and Neurotoxicities Related to Bispecific Antibodies
Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies
Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases
Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials
Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma
Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education